FSWA
CTXR icon

Financial Synergies Wealth Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

Financial Synergies Wealth Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8
Closed -$242 – 474
2022
Q3 		$242 Hold
8
– – ﹤0.01% 437
2022
Q2 		$184 Buy
+8
New +$219 ﹤0.01% 475

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Financial Synergies Wealth Advisors's CTXR Position: Q4 2022 in Review

Financial Synergies Wealth Advisors sold out of Citius Pharmaceuticals (CTXR) in Q4 2022, closing a stake of 8 shares — an estimated $242 sold.

Financial Synergies Wealth Advisors first reported a position in CTXR in Q2 2022 and held it in 2 quarters. The position peaked at $242 in Q3 2022. 54 funds tracked by Wall St. Rank hold CTXR as of Q4 2022.

  • Financial Synergies Wealth Advisors reported no remaining Citius Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Financial Synergies Wealth Advisors sold 8 Citius Pharmaceuticals shares in Q4 2022, an estimated $242.
  • Financial Synergies Wealth Advisors first reported a position in Citius Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Financial Synergies Wealth Advisors's Citius Pharmaceuticals position peaked at $242 in Q3 2022.
  • 54 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2022.

Based on Financial Synergies Wealth Advisors's 13F filing for Q4 2022, filed 4 Apr 2024.